PRTK Paratek Pharmaceuticals, Inc.

-0.65  -3%
Previous Close 20.75
Open 20.70
Price To book 6.30
Market Cap 552.45M
Shares 27,485,000
Volume 407,341
Short Ratio 2.00
Av. Daily Volume 819,755

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 23, 2011.
Phase 3 completion of enrollment announced May 8, 2017. Data due mid-July 2017. July 15 estimate based on company guidance of "mid-July".
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3 topline data met endpoints - June 2016
Acute bacterial skin and skin structure infections (ABSSSI)
Phase 3 data released April 3, 2017 - all endpoints met. Regulatory filing due 1Q 2018.
Community-acquired bacterial pneumonia (CABP)
Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
Severe acne vulgaris

Latest News

  1. Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017
  2. Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July
  3. Today's Research Reports on Arrowhead Pharmaceuticals and Paratek Pharmaceuticals Post Earnings
  4. Here's Why Paratek Pharmaceuticals Rose as Much as 16.1% Today
  5. Paratek reports 1Q loss
  6. Investor Network: Paratek Pharmaceuticals Inc to Host Earnings Call
  7. Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update
  8. Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017
  9. Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic (PK/PD) Data
  10. Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers
  11. New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals’ Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections
  12. Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China
  13. New Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathogens, Including MRSA
  14. Why Paratek Pharmaceuticals (PRTK) Could Be Positioned for a Surge?
  15. Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID 2017
  16. Paratek (PRTK) Stock Continues to Rise on Positive Results
  17. Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals
  18. Rising Biotechs: Paratek Among Stocks Surging On Trial Results
  19. Why Southwestern Energy, Paratek Pharmaceuticals, and AmTrust Financial Services Jumped Today
  20. Paratek Pharma's Pneumonia Antibiotic Succeeds

SEC Filings

  1. D - Notice of Exempt Offering of Securities 14900882
  2. 15-12G - Securities registration termination [Section 12(g)] 131065901
  3. 8-K - Current report 111170754
  4. NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 111112169
  5. 8-K - Current report 111110230
  6. 8-K - Current report 11986107
  7. 8-K - Current report 11851975
  8. 8-K - Current report 11825838
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 11822565
  10. 8-K - Current report 11720538